Mustang Bio closed at $0.41 on Nov 4, up 1.07%, 70.7% below its 52-week closing high. Volume of 4.0K shares was 0.10× its 20-day average (below normal).
Split-adjusted performance: -10.0% over one month, -44.6% over six months, -70.2% over one year.
Short interest was 58.9K shares at the Oct 15 settlement, up 11.7% from the prior report (1.0% of float, 1.1 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| MBIOMustang Bio | $0.4138 | +1.07% | −44.6% | — | — | — | $3.1M | |
| GRIGRI Bio | $1.43 | −7.14% | −39.4% | — | — | — | $3.1M | Compare |
| JUNSJupiter Neurosciences | $2.46 | +1.23% | −91.0% | — | −9380.9% | — | $3.2M | Compare |
| SILOSilo Pharma | $1.33 | +3.91% | −78.9% | −100.0% | — | — | $2.9M | Compare |
| SXTP60 Degrees Pharmaceuticals | $0.9563 | −5.32% | −42.4% | −32.5% | −1152.6% | — | $3.4M | Compare |
| KALAKALA BIO | $0.1781 | +2.95% | −96.9% | — | — | — | $3.4M | Compare |
| MDCXMedicus Pharma | $1.88 | −7.39% | −88.7% | — | — | — | $3.6M | Compare |
| CVKDCadrenal Therapeutics | $1.06 | −6.19% | −82.8% | — | — | — | $3.8M | Compare |
| ONCOOnconetix | $0.6583 | +15.69% | −85.4% | −83.9% | −16748.3% | — | $3.9M | Compare |
No recent articles focused on Mustang Bio. 1 articles mention it in passing.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
